

References

S-137

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Nonsmall cell lung cancer. Version 4.2022.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 2.022.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 1.2022.
4. Oc Y, Kilinc BE, Cennet S, et al. Complications of computer tomography assisted radiofrequency ablation in the treatment of osteoid osteoma. *BioMed Res Int.* 2019;1-6.
5. National Institute for Health and Care Excellence (NICE). Percutaneous radiofrequency ablation of renal cancer. 2010.
6. Tordjman M, Perronne L, Madelin G, et al. CT-guided radiofrequency ablation for osteoid osteomas: A systematic review. *Eur Radiol.* 2020;30(11):5952-5963.
7. Sahin C, Oc Y, Ediz N, et al. The safety and the efficacy of computed tomography guided percutaneous radiofrequency ablation of osteoid osteoma. *Acta Orthop Traumatol Turc.* 2019;53(5):360-365.
8. Hasegawa T, Takaki H, Kodama H, et al. Three-year survival rate after radiofrequency ablation for surgically resectable colorectal lung metastases: A prospective multicenter study. *Radiology.* 2020;294(3):686-695.
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancer. Version 2.2022.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 4.2022.
11. Barthet M, Giovannini M, Lesavre N, et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: A prospective multicenter study. *Endoscopy.* 2019;51(9):836-842.
12. Hlavsa J, Procházka V, Andrasina T, et al. Radiofrequency ablation in pancreatic cancer. *Rozhl Chir.* 2019;98(11):441-449.
13. Oh D, Ko SW, Seo DW, et al. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic microcystic serous cystic neoplasms: A retrospective study. *Endoscopy.* 2021;53(7):739-743.
14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 2.2023.
15. InterQual® Level of Care Criteria 2021. Acute Care Adult. McKesson Health Solutions, LLC.

16. Uhlig J, Strauss A, Rucker G, Seif Amir Hosseini A, et al. Partial nephrectomy versus ablativetechniques for small renal masses: A systematic review and network meta-analysis. *Eur Radiol.* 2019;29(3):1293-1307.
17. Marshall HR, Shakeri S, Hosseiny M, Sisk A, et al. Long-term survival after percutaneous radiofrequency ablation of pathologically proven renal cell carcinoma in 100 patients. *J Vasc Interv Radiol.* 2020;31(1):15-24.
18. Andrews JR, Atwell T, Schmit G, Lohse CM, et al. Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses. *Eur Urol.* 2019;76(2):244-251.
19. Ierardi AM, Carnevale A, Angileri SA, Pellegrino F, et al Outcomes following minimally invasive imagine-guided percutaneous ablation of adrenal glands. *Gland Surg.* 2020;9(3):859-866.
20. Yan S, Yang W, Zhu CM, et al. Comparison among cryoablation, radiofrequency ablation, and partial nephrectomy for renal cell carcinomas sized smaller than 2 cm or sized 2-4 cm: A population-based study. *Medicine (Baltimore).* 2019;98(21):e15610.
21. Morkos J, Porosnicu Rodriguez KA, Zhou A, et al. Percutaneous cryoablation for stage 1 renal cell carcinoma: Outcomes from a 10-year prospective study and comparison with matched cohorts from the National Cancer database. *Radiology.* 2020;296(2):452-459.
22. Stacul F, Sachs C, Giudici F, et al. Cryoablation of renal tumors: Long-term followup from a multicenter experience. *Abdom Radiol (NY).* 2021;46(9):4476-4488.
23. Callstrom MR, Woodrum DA, Nichols FC, et al. Multicenter study of metastatic lung tumors targeted by interventional cryoablation evaluation (SOLSTICE). *J Thorac Oncol.* 2020;15(7):1200-1209.
24. Takada M, Toi M. Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. *Int J Clin Oncol.* 2019;24(6):608-613.
25. Fine RE, Gilmore RC, Dietz JR, et al. Cryoablation without excision for low-risk early-stage breast cancer: 3-Year interim analysis of ipsilateral breast tumor recurrence in the ICE3 trial. *Ann Surg Oncol.* 2021.
26. Wu Y, Gu Y, Zhang B, et al. Laparoscopic ultrasonography-guided cryoablation of locally advanced pancreatic cancer: A preliminary report. *Jpn J Radiol.* 2021.
27. Jennings JW, Prologo JD, Garnon J, et al. Cryoablation for palliation of painful bone metastases: The MOTION multicenter study. *Radiol Imaging Cancer.* 2021;3(2):e200101.
28. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Bone Cancer. Version 1.2023.
29. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 4.2022.

30. Hayes, Inc. Hayes Health Technology Assessment. Radiofrequency Ablation for Benign Thyroid Nodules. Lansdale, PA: Hayes, Inc.; 06/29/2021.
31. Gray RE, Harris GT. Renal cell carcinoma: Diagnosis and management. *Am Fam Physician*. 2019;99(12):732.
32. Sebek J, Taeprasartsit P, Wibowo H, Beard WL, Bortel R, Prakash P. Microwave ablation of lung tumors: A probabilistic approach for simulation-based treatment planning. *Med Phys*. 2021;48(7):3991-4003.
33. Cazzato RL, Jennings JW, Autrusseau P-A, et al. Percutaneous image-guided cryoablation of spinal metastases: Over 10-year experience in two academic centers. *Euro Radiol*. 2022;32(6):4137-4146.
34. Levy, J., Hopkins, T., Morris, J., et al. Radiofrequency ablation for the palliative treatment of bone metastases: Outcomes from the multicenter OsteoCool Tumor Ablation Post-Market Study (OPuS One Study) in 100 patients. *J Vasc Interv Radiol*, 2020; 31(11):1745-1752.
35. Xv, Z., Wang, X., Ke, H., & Lyu, G. Cryoablation is superior to radiofrequency ablation for the treatment of non-small cell lung cancer: A meta-analysis. *Cryobiology*, 2023;104560.